Botswana 'Treat All' Program Will Move to Universal Treatment With Dolutegravir as First-Line ART

May/June 2016

On 3 June 2016, a press release from ViiV Healthcare announced an agreement with the Botswana Ministry of Health for dolutegravir to be commissioned as first-line therapy.1

This will be part of a national "Treat All" public health programme to provide universal access to HIV treatment in Botswana.

Botswana is the first country in sub-Saharan Africa to move to using dolutegravir as first-line therapy -- bringing the country in line with guidelines high-income countries that moved to recommend integrase inhibitor combinations rather than starting treatment with efavirenz.

Dolutegravir brings viral load down quicker and more effectively than efavirenz. It is associated with fewer side effects and a lower risk of drug resistance.

The low milligram dose needed for dolutegravir (50 mg vs 600 mg for efavirenz) helped the Clinton Health Access Initiative (CHAI) negotiate for the price of generic dolutegravir to be comparable to generic efavirenz.2

WHO recommended dolutegravir as part of alternative first-line ART in late 2015.


  1. ViiV press release. ViiV Healthcare announces public tender agreement with Botswana Ministry of Health for dolutegravir. (03 June 2016).
  2. Collins S. Better generic ART for low and middle income countries: dolutegravir at US $44 a year. HTB January/February 2016.

This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.